Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN

Liminatus Pharma, Inc.

Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.
Liminatus develops anti-CD47 monoclonal antibody IBA101 for advanced solid cancers including non-small cell lung cancer.
Leadership: CEO Chris Kim, CFO Scott Dam, CSO Byong C. Yoo.
Business Combination approved at Iris stockholders meeting on March 4, 2025.
Advisors: Holland & Knight for Iris, Loeb & Loeb for Liminatus, Raymond James.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.